ATE212233T1 - Impfstoffe gegen neisseria meningitidis gruppe c - Google Patents

Impfstoffe gegen neisseria meningitidis gruppe c

Info

Publication number
ATE212233T1
ATE212233T1 AT93921251T AT93921251T ATE212233T1 AT E212233 T1 ATE212233 T1 AT E212233T1 AT 93921251 T AT93921251 T AT 93921251T AT 93921251 T AT93921251 T AT 93921251T AT E212233 T1 ATE212233 T1 AT E212233T1
Authority
AT
Austria
Prior art keywords
gcmp
conjugate
modified
neisseria meningitidis
vaccines against
Prior art date
Application number
AT93921251T
Other languages
English (en)
Inventor
Francis Michon
Harold Jennings
Joseph Y Tai
Lucjan J J Hronowski
Sharon Mates
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/938,367 external-priority patent/US5425946A/en
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Application granted granted Critical
Publication of ATE212233T1 publication Critical patent/ATE212233T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
AT93921251T 1992-08-31 1993-08-30 Impfstoffe gegen neisseria meningitidis gruppe c ATE212233T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/938,367 US5425946A (en) 1992-08-31 1992-08-31 Vaccines against group C Neisseria meningitidis
US6450193A 1993-05-19 1993-05-19
PCT/US1993/008155 WO1994005325A1 (en) 1992-08-31 1993-08-30 Vaccines against group c neisseria meningitidis

Publications (1)

Publication Number Publication Date
ATE212233T1 true ATE212233T1 (de) 2002-02-15

Family

ID=26744584

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93921251T ATE212233T1 (de) 1992-08-31 1993-08-30 Impfstoffe gegen neisseria meningitidis gruppe c

Country Status (12)

Country Link
EP (1) EP0658118B1 (de)
JP (2) JP4097691B2 (de)
AT (1) ATE212233T1 (de)
AU (1) AU4841693A (de)
CA (1) CA2142981C (de)
DE (1) DE69331495T2 (de)
DK (1) DK0658118T3 (de)
ES (1) ES2171418T3 (de)
NO (1) NO323616B1 (de)
PL (1) PL175595B1 (de)
PT (1) PT658118E (de)
WO (1) WO1994005325A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780606A (en) * 1995-06-07 1998-07-14 Connaught Laboratories Limited Neisseria meningitidis capsular polysaccharide conjugates
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
WO1998058670A1 (en) * 1997-06-24 1998-12-30 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
WO2001078787A2 (en) * 2000-04-18 2001-10-25 Endobiologics, Incorporated Lipopolysaccharide-conjugate vaccine for sepsis treatment
US7749511B2 (en) 2000-04-18 2010-07-06 Endobiologics, Incorporated Anti-sepsis conjugate vaccine
SI21352A (sl) * 2001-01-23 2004-06-30 Aventis Pasteur Multivalentno meningokokno cepivo iz konjugata polisaharida-proteina
CA2530364C (en) * 2003-06-23 2014-03-18 Baxter International Inc. Vaccines against group y neisseria meningitidis and meningococcal combinations thereof
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
NZ546430A (en) 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
NZ550533A (en) 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
PL2004225T3 (pl) 2006-03-22 2012-09-28 Novartis Ag Schematy immunizacji koniugatami meningokokowymi
ES2555786T3 (es) 2007-06-04 2016-01-08 Glaxosmithkline Biologicals Sa Formulación de vacunas contra la meningitis
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
WO2010070453A2 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
EP2373333A1 (de) * 2008-12-22 2011-10-12 Children's Hospital & Research Center at Oakland Ex-vivo-bakteriämietest mit passivem schutz
EP2411048B1 (de) 2009-03-24 2020-05-06 GlaxoSmithKline Biologicals SA Adjuvantierendes meningokokken-faktor-h-bindungsprotein
EP3017826A1 (de) 2009-03-24 2016-05-11 Novartis AG Kombinationen von meningokkoken-faktor-h-bindenden proteinen und pneumokokken-saccharid-konjugaten
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
EP2729178A1 (de) 2011-07-08 2014-05-14 Novartis AG Tyrosinverbindungsverfahren
RU2636350C2 (ru) 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
EP2822584A1 (de) 2012-03-08 2015-01-14 Novartis AG Kombinationsimpfstoffe mit tlr4-agonisten
JP6324961B2 (ja) 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
US20150320852A1 (en) 2012-12-18 2015-11-12 Glaxosmithkline Biologicals Sa Conjugates for protecting against diphtheria and/or tetanus
AU2014286990A1 (en) 2013-07-11 2016-02-11 Novartis Ag Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
MY186874A (en) * 2014-02-25 2021-08-26 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd A novel downstream process for purifying polysaccharides
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
BR112019003992A2 (pt) * 2016-09-02 2019-05-28 Sanofi Pasteur Inc vacina contra neisseria meningitidis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.

Also Published As

Publication number Publication date
AU4841693A (en) 1994-03-29
ES2171418T3 (es) 2002-09-16
DK0658118T3 (da) 2002-05-06
JP2008044955A (ja) 2008-02-28
WO1994005325A1 (en) 1994-03-17
JPH08500607A (ja) 1996-01-23
PT658118E (pt) 2002-05-31
NO950739L (no) 1995-04-26
EP0658118A4 (de) 1995-09-13
DE69331495D1 (de) 2002-03-14
CA2142981C (en) 2007-10-23
EP0658118A1 (de) 1995-06-21
PL307745A1 (en) 1995-06-12
NO323616B1 (no) 2007-06-18
JP4097691B2 (ja) 2008-06-11
NO950739D0 (no) 1995-02-27
DE69331495T2 (de) 2002-10-31
EP0658118B1 (de) 2002-01-23
PL175595B1 (pl) 1999-01-29
CA2142981A1 (en) 1994-03-17

Similar Documents

Publication Publication Date Title
ATE212233T1 (de) Impfstoffe gegen neisseria meningitidis gruppe c
ES8707861A1 (es) Un metodo para preparar un conjugado inmunogeno
YU24391A (sh) Poboljšana meningokokna polisaharid kon-jugovana vakcina
ATE287947T1 (de) Orale immunisierung durch verwendung von transgenen pflanzen
FI912965A0 (fi) Vaccin innehaollande protein fraon klass 1-yttermembranen av meningokocker.
DK0778781T3 (da) Pneumokok-polysaccharid-rekombinant pneumolysin-konjugat-vacciner til immunisering mod pneumokokinfektioner
RU2009134033A (ru) Жидкие вакцины для множественных серогрупп менингококков
NO306905B1 (no) Oligosakkarid avledet fra antigent polysakkarid erholdt fra et patogen
ATE529130T1 (de) Trockenformulierung für transkutane immunisierung
AU570405B2 (en) Conjugates of muramyl-peptides and haptenes
DK0994721T3 (da) Nervevækstfaktor som vaccineadjuvans
DK341679A (da) Vaccine mod streptokokker og fremgangsmaade til fremstilling deraf
Klipstein et al. Immunological interrelationships between cholera toxin and the heat-labile and heat-stable enterotoxins of coliform bacteria
ES2126616T3 (es) Vacuna pediatrica combinada, con una inmunogenecidad aumentada de cada componente de la vacuna.
RU93048161A (ru) Комбинированная педиатрическая вакцина с усиленной иммуногенностью каждого вакционного компонента
NO913131L (no) Immunogene konjugater av ikke-toksisk oligosakkarid fra bordetella pertussis lipoolysakkarid.
WO2002038611A3 (en) Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
Schneerson et al. Semi-Synthetic Vaccines Composed of Capsular Polysaccharides of Pathogenic Bacteria Covalently
ATE145335T1 (de) Kreuzreaktive immunisierung gegen influenza
SHAMS et al. The effect of conjugation on immunogenicity and potency of protein carriers of polyribosylribitol phosphate (PRP) conjugated vaccines in the mouse model
MÄKELÄ et al. Vaccines for Haemophilus influenzae type b as models for an otitis vaccine
Kosenkova et al. Specific features of the formation of immunity after the primary complex of immunization with adsorbed DPT vaccine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification